InVivo Therapeutics (Nasdaq:NVIV) announced today that it entered into a definitive agreement to offer $9 million in common stock. Cambridge, Massachusetts-based InVivo entered the agreement with a single healthcare-focused institutional investor. The registered direct offering covers the sale and issuance of 523,810 shares of the Company’s common stock (or pre-funded warrants in lieu thereof). In […]
InVivo Therapeutics
InVivo Therapeutics completes enrollment in study of Nuero-Spinal Scaffold
InVivo Therapeutics (Nasdaq:NVIV) announced today that it completed enrollment in the Inspire 2.0 study for patients with acute spinal cord injury. Cambridge, Massachusetts–based InVivo’s 20-patient randomized, controlled trial aims to enhance the clinical evidence for the company’s Neuro-Spinal Scaffold. The company designed the Neuro-Spinal Scaffold to encourage functional cells to fill a cavity that will […]
Invivo Therapeutics raises $3m
InVivo Therapeutics (NSDQ:NVIV) filed an SEC Form D to confirm the sale of more than $3 million in options, warrants and/or other rights to acquire other securities. The Cambridge, Mass.-based spinal cord injury treatment developer sold its entire offering amount of $3,022,576. It included a private placement of warrants to purchase more than 1.7 million shares […]
InVivo Therapeutics prices $7m offering
InVivo Therapeutics (NSDQ:NVIV) announced last week that it priced a public offering of common stock shares and warrants totaling approximately $7 million. The offering is set to include more than 2.5 million shares of common stock or pre-funded warrants to purchase common stock, along with standard warrants to purchase up to more than 2.5 million shares […]
InVivo Therapeutics stock down after reverse stock split
InVivo Therapeutics’ (NSDQ:NVIV) recently announced 1-for-30 reverse stock split went into effect last night, and shares have taken a hit today as a result. NVIV was down -10.2% at $6.95 per share in midday trading today. Cambridge, Mass.–based spinal cord injury treatment developer initially announced the common stock split earlier this month, sharing that every 30 […]
InVivo prices $1m public stock offering
InVivo Therapeutics (NSDQ:NVIV) announced that it priced a public stock offering expected to produce gross proceeds of just under $1 million for the company. The Cambridge, Mass.-based company is offering 7 million shares of its common stock to the public at a price of 12¢ per share. InVivo expects the gross proceeds to reach $840,000, before […]
Pixarbio CEO Reynolds convicted in $13m investor fraud case
Pixarbio founder & CEO Frank Reynolds reportedly faces two decades behind bars after a jury yesterday convicted him of defrauding investors of nearly $13 million. Federal authorities arrested Reynolds, longtime friend and Pixarbio employee Jay Herod and PixarBio CIO Kenneth Stromsland in April 2018 on securities fraud charges, claiming they misled investors about the opioid substitute […]
InVivo Therapeutics launches new neuro-spinal scaffold study
InVivo Therapeutics (NSDQ:NVIV) said today that it launched a new trial of its neuro-spinal scaffold, dubbed the INSPIRE 2.0 study, and that it has enrolled the first two patients into the study. The Cambridge, Mass.-based company won FDA approval to launch the new pivotal study of the device last March, after ending the previous Inspire study of the […]
InVivo Therapeutics releases 12-month Inspire study results
InVivo Therapeutics (NSDQ:NVIV) yesterday presented twelve-month results from the single-arm INSPIRE study of its neuro-spinal scaffold. The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. Results from the trial were presented at the 2019 AANS Meeting in […]
JenaValve names Kilcoyne as CEO | Personnel Moves – January 15, 2019
JenaValve Technology said today that it named former ReVision Optics prez & CEO John Kilcoyne as its new chief executive officer, effective immediately, replacing Dr. Victoria Carr-Brendell, who has taken up an executive leadership position with Sonova Holding AG (SIX:SOON). Prior to his time at ReVision Optics, Kilcoyne served as prez & CEO at Micrus Endovascular where he […]
InVivo inks joint research deal with cell therapy dev Q Therapeutics
InVivo Therapeutics (NSDQ:NVIV) said today it inked a joint research agreement with clinical-stage central nervous system cell therapy developer Q Therapeutics. Through the deal, InVivo is looking to combine its neuro-spinal scaffold technology with Q Therapeutics’ adult neural progenitor cells, Cambridge, Mass.-based InVivo said. Both companies will share their technologies and explore the potential combination’s safety […]
